# SBRT Plus vNKT for Pancreatic Cancer

> **NCT05783076** · PHASE2 · UNKNOWN · sponsor: **Changhai Hospital** · enrollment: 29 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Stereotactic body radiation therapy
- **DRUG:** adoptive cell therapy with vNKT cells

## Key facts

- **NCT ID:** NCT05783076
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-25
- **Primary completion:** 2024-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2023-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05783076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05783076, "SBRT Plus vNKT for Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05783076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*